Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial
AIDS, Volume 16, No. 5, Year 2002
Notification
URL copied to clipboard!
Description
Objective: To assess the respective value of phenotype versus genotype versus standard of care for choosing antiretroviral therapy in patients failing protease inhibitor-containing regimens. Methods: Patients with plasma HIV-1 RNA exceeding 1000 copies/ml were randomly allocated to phenotyping, genotyping, or standard of care. Results: Five-hundred and forty-one patients were randomized, 190 to phenotyping, 192 to genotyping and 159 to standard of care. The baseline median CD4 cell count (280 × 106 cells/I), the plasma HIV-1 RNA level (4.3 log10 copies/ml), and the number of drugs previously received (n = 6) were similar in the three arms. More patients in the standard-of-care arm received at least three new drugs (55% versus 20% in the other arms; P < 0.001) and a regimen containing drugs from the three different classes. Plasma HIV-1 RNA was < 200 copies/ml at week 12 in 35% of patients in the phenotyping arm, 44% in the genotyping arm and 36% in the standard-of-care arm (phenotyping versus standard of care, P = 0.918; genotyping versus standard of care, P = 0.120). In a secondary analysis of 179 patients experiencing a first protease inhibitor failure, the percentage of patients achieving HIV-1 RNA < 200 copies/ml was significantly higher in the genotyping arm (65%) than in the phenotyping (45%) and the standard-of-care arms (45%) (genotyping versus standard of care, P = 0.022). Conclusions: Overall, resistance assays did not demonstrate benefit over standard of care. In patients with the most limited protease inhibitor experience, a significant benefit was observed in the genotyping arm. © 2002 Lippincott Williams & Wilkins.
Authors & Co-Authors
Meynard, Jean Luc
France, Paris
Hôpital Saint-antoine
France, Paris
Hôpital Rothschild
Vray, Muriel M.
France, Paris
Hôpital Saint-antoine
France, Paris
Inserm
France, Paris
Hôpital Rothschild
Morand-Joubert, Laurence
France, Paris
Hôpital Saint-antoine
France, Paris
Hôpital Rothschild
Descamps, Diáne
France, Paris
Hôpital Saint-antoine
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
France, Paris
Hôpital Rothschild
Peytavin, Gilles
France, Paris
Hôpital Saint-antoine
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
France, Paris
Hôpital Rothschild
Matheron, Sophie
France, Paris
Hôpital Saint-antoine
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
France, Paris
Hôpital Rothschild
Costagliola, Dominique G.
France, Paris
Hôpital Saint-antoine
France, Paris
Inserm
France, Paris
Hôpital Rothschild
Brun-Vézinet, Françoise
France, Paris
Hôpital Saint-antoine
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
France, Paris
Hôpital Rothschild
Clavel, François
France, Paris
Hôpital Saint-antoine
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
France, Paris
Hôpital Rothschild
Girard, Pierre Marie
France, Paris
Hôpital Saint-antoine
France, Paris
Hôpital Rothschild
Statistics
Citations: 216
Authors: 10
Affiliations: 4
Identifiers
Doi:
10.1097/00002030-200203290-00008
ISSN:
02699370
Research Areas
Genetics And Genomics
Infectious Diseases